Charles Schwab Investment Management Inc Aerovate Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 29,351 shares of AVTE stock, worth $73,964. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,351
Previous 29,351
-0.0%
Holding current value
$73,964
Previous $61,000
26.23%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding AVTE
# of Institutions
83Shares Held
30.7MCall Options Held
186KPut Options Held
269K-
Ra Capital Management, L.P. Boston, MA9.19MShares$23.2 Million0.39% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$9.47 Million0.81% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$5.65 Million0.97% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.53 Million0.79% of portfolio
-
Braidwell LP Stamford, CT1.44MShares$3.63 Million0.21% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $61.6M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...